First comes diagnosis then comes treatment: An underappreciated paradigm in atrial fibrillation management

European Heart Journal

Volumn 26, Issue 23, 2005, Pages 2487-2489

  Bollmann, Andreas ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; AUTONOMIC DYSFUNCTION; BRAIN INFARCTION; CORONARY RISK; DISEASE COURSE; ECHOCARDIOGRAPHY; EDITORIAL; ELECTROPHYSIOLOGY; EMBOLISM; FOLLOW UP; GENETIC PREDISPOSITION; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; PRIORITY JOURNAL; STROKE; SURVIVAL; THROMBOGENESIS; THROMBOSIS;

ATRIAL FIBRILLATION; HUMANS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 27944504006     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi578     Document Type: Editorial

References (11)

1. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Alonso-Garcia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation: Executive Summary a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-2150.
2. Osranek M, Bursi F, Bailey KR, Grossardt BR, Brown RD Jr, Kopecky SL, Tsang TS, Seward JB. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three decade follow-up. Eur Heart J 2005;26:2556-2561. First published on September 1, 2005, doi:10.1093/eurheartj/ehi483.
3. NIH Definitions Working Group. Biomarkers and Surrogate Endpoints in Clinical Research: Definitions and Conceptual Model. Amsterdam: Elsevier; 2000.
4. Moller JE, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS, Park SW, Bailey KR, Pellikka PA. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 2003;107:2207-2212.
5. Rossi A, Cicoira M, Zanolla L, Sandrini R, Golia G, Zardini P, Enriquez-Sarano M. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002;40:1425-1430.
6. Bollmann A, Binias K, Grothues F, Sonne K, Esperer H, Nikutta P, Klein H. Left atrial appendage flow in nonrheumatic atrial fibrillation: relationship with pulmonary venous flow and ECG fibrillatory wave amplitude. Chest 2001;119:485-492.
7. Bollmann A, Husser D, Stridh M, Soernmo L, Majic M, Klein HU, Olsson SB. Frequency measures obtained from the surface electrocardiogram in atrial fibrillation research and clinical decision-making. J Cardiovasc Electrophysiol 2003;14:S154-S161.
8. Prentice H, Webster KA. Genomic and proteomic profiles of heart disease. Trends Cardiovasc Med 2004;14:282-288.
9. Li D, Benardeau A, Nattel S. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 2000;102:104-112.
10. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-2614.
11. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62:105-111.